



## ASX ANNOUNCEMENT

2 May 2025

# COMPLETION OF \$1.5 MILLION OVERSUBSCRIBED PLACEMENT

Opyl Limited (“**OPL**” or “the **Company**”) is pleased to announce that it has received firm commitments for a strategic placement to raise \$1,500,000 to accelerate the building and growth of its advanced AI powered drug discovery platform, Trialkey.

This strategic funding supports OPL’s investment in:

- Trialkey sales, marketing, and support
- Trialkey development and infrastructure
- General working capital

“We’re incredibly grateful to our investors for their confidence and support in this next phase of our journey. This raise was heavily oversubscribed, reflecting the strong belief in TrialKey’s mission and the momentum we’re building. These funds will enable us to accelerate the development and commercial expansion of our AI-powered platform, ensuring faster, smarter, and more predictive clinical trial design across global markets.”

— Saurabh Jain, Executive Chairman, Opyl (ASX: OPL)

The placement was notably supported by Director Antanas Guoga (Tony G)

“I’m absolutely delighted to have taken part in this oversubscribed raise. The enthusiasm from fellow investors confirms just how powerful TrialKey’s vision is, and I’m excited to help propel the next phase of growth as we scale our AI-driven platform worldwide.”

— Antanas “Tony G” Guoga, Investor & Non-Executive Director, Opyl (ASX: OPL)

For personal use only



## Placement Details

OPL has received firm commitments from eligible sophisticated and institutional investors to raise approximately \$1,500,000 (before costs) (**Placement**) through the issue of approximately 71,428,572 fully paid ordinary shares (**Placement Shares**) at an issue price of \$0.021 per Placement Share, together with one-free attaching option exercisable at \$0.03 and expiry of four years from the issue date for every two (2) Placement Share subscribed for and issued under the Placement (**Attaching Option**). The Attaching Options will be issued subject to Company Shareholder Approval.

The Placement issue price of \$0.021 per share represents:

- a 19.2% discount to the last close price of Tuesday, 29 April 2025 (A\$0.026); and
- a 23.4% discount to the 15-day volume weighted average price (VWAP) of A\$0.027).

The Shares issued under the Placement will be issued pursuant to the Company's available placement capacity as follows:

- 25,107,195 Shares under ASX Listing Rule 7.1; and
- 16,892,805 Shares under ASX Listing Rule 7.1A, (together **Tranche 1 Placement**).

The issue of the remaining 29,428,572 Placement Shares (which will include Tony G's participation) and 35,714,286 Attaching Options (**Tranche 2 Placement**) is subject to Shareholder approval, which the Company intends to seek at a general meeting proposed to be held in June 2025 (**June EGM**).

Sandton Capital Advisory Pty Ltd and GBA Capital Pty Ltd acted as joint lead managers to the Placement.



## Indicative Timetable\*

Placement	
Settlement of Tranche 1 Placement	Friday, 9 May 2025
Allotment of Shares under Tranche 1 Placement	Monday, 13 May 2025
Commencement of trading of Shares under Tranche 1 Placement	Monday, 13 May 2025
General Meeting to approve Tranche 2 Placement*	Tuesday, 10 June 2025
Settlement of Tranche 2 Placement	Wednesday, 11 June 2025
Allotment and commencement of trading of shares issued under Tranche 2 Placement	Thursday, 12 June 2025

\*These dates are subject to change and may be adjusted based on prevailing circumstances and requirements. Any updates or amendments to the timetable will be communicated in a timely manner.

**This announcement has been authorised for release by the Board**

**-ENDS-**

### For investor enquiries:

Bernice Averion  
Head of Marketing and Communications  
Phone: +61 415 311 957  
Email: [bernice@trialkey.ai](mailto:bernice@trialkey.ai)

### About Opyl Limited (ASX: OPL)

Opyl Limited is an AI company dedicated to leveraging data and technology to transform the landscape of clinical trials and medical research. With a commitment to innovation and strategic growth, Opyl is positioned to lead the way in shaping the future of healthcare solutions.